Today we're asking Nathalie Moll, Director General of EFPIA:
"How can we future-proof medicines regulation in the post-COVID world?".
Europe’s regulatory system is designed to ensure that new treatments for patients are safe and effective. It has helped to extend and improve the lives of millions of people across Europe and beyond. But to keep pace with developments in science and technology and to remain competitive in the face of fierce global competition, Europe’s regulatory framework has to evolve.
The EU Health Coalition calls on the Portuguese presidency of the Council of the EU to work towards the establishment of a forum for better access to health innovation. Read more
Scientists said the neutralising ability was roughly equivalent to the vaccine's effect on a previous less contagious...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.